{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:58:54Z","timestamp":1792432734994,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jconrel.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:59:05Z","timestamp":1646477945000},"page":"75-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["DMPC\/Chol liposomal copper CX5461 is therapeutically superior to a DSPC\/Chol formulation"],"prefix":"10.1016","volume":"345","author":[{"given":"Ada W.Y.","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent T.J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathi","family":"Anantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wretham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynab","family":"Nosrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon","family":"Heroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongye","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel B.","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.03.004_bb0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/ml300110s","article-title":"Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for Cancer therapeutics","volume":"3","author":"Haddach","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0010","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc.2017.104","article-title":"Ribosome biogenesis in cancer: new players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0020","doi-asserted-by":"crossref","first-page":"49800","DOI":"10.18632\/oncotarget.10452","article-title":"Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM\/ATR signaling","volume":"7","author":"Quin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0025","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0030","first-page":"4053","article-title":"The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning","volume":"117","author":"Bruno","year":"2020"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1534\/genetics.120.303169","article-title":"A multimodal genotoxic anticancer drug characterized by pharmacogenetic analysis in Caenorhabditis elegans","volume":"215","author":"Ye","year":"2020","journal-title":"Genetics"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0040","doi-asserted-by":"crossref","first-page":"e22212","DOI":"10.1200\/jco.2015.33.15_suppl.e22212","article-title":"A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM)","volume":"33","author":"Harrison","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy048.003","article-title":"44OCCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","volume":"29","author":"Hilton","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0050","series-title":"First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study","author":"Khot","year":"2019"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0055","series-title":"Abstract PD4\u201302: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"80","author":"Hilton","year":"2020"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0060","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1002\/chem.201800289","article-title":"Transition metal ions promote the bioavailability of hydrophobic therapeutics: cu and Zn interactions with RNA polymerase I inhibitor CX5461","volume":"24","author":"Prosser","year":"2018","journal-title":"Chemistry"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.07.025","article-title":"Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor","volume":"286","author":"Leung","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0075","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0080","doi-asserted-by":"crossref","first-page":"738","DOI":"10.21037\/jgo.2016.05.04","article-title":"Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?, journal of","volume":"7","author":"Teo","year":"2016","journal-title":"Gastrointest. Oncol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0085","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13053-015-0038-x","article-title":"The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers","volume":"13","author":"Cavanagh","year":"2015","journal-title":"Hereditary Cancer in Clinical Practice"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers, brit","volume":"111","author":"Golan","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0100","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precision Oncol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1586\/14737140.2015.1086271","article-title":"Pancreatic cancer: BRCA mutation and personalized treatment","volume":"15","author":"Luo","year":"2015","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/CAD.0000000000000178","article-title":"Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation","volume":"26","author":"Vyas","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0115","first-page":"33","article-title":"Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages, Biochimica et Biophysica Acta (BBA)","volume":"931","author":"Derksen","year":"1987","journal-title":"Mol. Cell Res."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0120","series-title":"Liposome Technology: Pharmacodynamics of Liposomal Drug Carriers: Methodology Considerations","author":"Bally","year":"2006"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0125","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00001813-199911000-00007","article-title":"Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models","volume":"10","author":"Bandak","year":"1999","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0130","series-title":"A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs","first-page":"6387","volume":"46","author":"Matsumura","year":"1986"},{"issue":"3","key":"10.1016\/j.jconrel.2022.03.004_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular Targeting Delivery of Liposomal Drugs to Solid Tumors Based on EPR Effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0140","series-title":"Transmembrane Ammonium Sulfate Gradients in Liposomes Produce Efficient and Stable Entrapment of Amphipathic Weak Bases","first-page":"201","volume":"1151","author":"Haran","year":"1993"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0145","series-title":"A Rigorous Theory of Remote Loading of Drugs into Liposomes","first-page":"3356","volume":"11","author":"Ceh","year":"1995"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0939-6411(00)00127-2","article-title":"Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC\/cholesterol liposomes under accelerated conditions: part 1: lipid hydrolysis","volume":"50","author":"Zhang","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(24)36596-6","article-title":"Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone","volume":"281","author":"Lim","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0160","series-title":"Influence of Vesicle Size, Lipid Composition, and Drug-to-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin in Mice","first-page":"5922","volume":"49","author":"Mayer","year":"1989"},{"issue":"1-2","key":"10.1016\/j.jconrel.2022.03.004_bb0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbamem.2004.03.006","article-title":"Drug Release Rate Influences the Pharmacokinetics, Biodistribution, Therapeutic Activity, and Toxicity of Pegylated Liposomal Doxorubicin Formulations in Murine Breast Cancer","volume":"1663","author":"Charrois","year":"2004","journal-title":"Biochim. Biophys. Acta."},{"issue":"1","key":"10.1016\/j.jconrel.2022.03.004_bb0170","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(24)36596-6","article-title":"Influence of Drug Release Characteristics on the Therapeutic Activity of Liposomal Mitoxantrone","volume":"281","author":"Lim","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10717540490265243","article-title":"The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations","volume":"11","author":"Anderson","year":"2004","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0180","series-title":"Lipids, Chemical Stability of Liposomes: Implications for their Physical Stability","first-page":"3","volume":"64","author":"Grit","year":"1993"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071026","article-title":"Spatiotemporal pH heterogeneity as a promoter of Cancer progression and therapeutic resistance","volume":"11","author":"Korenchan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0190","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126336","article-title":"Inter-metastatic heterogeneity of tumor marker expression and microenvironment architecture in a preclinical Cancer model","volume":"22","author":"Kalra","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0205","series-title":"Metal complexes in aqueous solutions","author":"Martell","year":"2013"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40495-017-0096-z","article-title":"Modeling enterohepatic circulation","volume":"3","author":"Okour","year":"2017","journal-title":"Curr. Pharmacol. Reports"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0215","series-title":"First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study","first-page":"1036","volume":"9","author":"Khot","year":"2019"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0220","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nature Rev. Mater."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0225","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0230","series-title":"New Insights into \u201cPermeability\u201d as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics","author":"Nel","year":"2017"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0235","series-title":"Influence of Vesicle Size, Lipid Composition, and Drug-To-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin in Mice","first-page":"5922","volume":"49","author":"Mayer","year":"1989"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0240","series-title":"Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency","first-page":"5696","volume":"8","author":"Sykes","year":"2014"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.actbio.2020.01.039","article-title":"Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy","volume":"106","author":"Sun","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0250","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nmat3792","article-title":"Strategies for advancing cancer nanomedicine","volume":"12","author":"Chauhan","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1758834012446008","article-title":"Overcoming the Stromal Barrier: Technologies to Optimize Drug Delivery in Pancreatic Cancer","volume":"4","author":"Dimou","year":"2012","journal-title":"Therapeut. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0260","series-title":"Enhanced Distribution of NK012, a Polymeric Micelle-Encapsulated SN-38, and Sustained Release of SN-38 Within Tumors can Beat a Hypovascular Tumor","first-page":"1258","volume":"99","author":"Saito","year":"2008"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0265","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3748\/wjg.v24.i7.794","article-title":"Translational pancreatic cancer research: A comparative study on patient-derived xenograft models","volume":"24","author":"Rubio-Manzanares Dorado","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0270","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acsnano.5b02017","article-title":"The role of micelle size in tumor accumulation, penetration, and treatment","volume":"9","author":"Wang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0275","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1021\/nn500299p","article-title":"Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency","volume":"8","author":"Sykes","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0280","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","article-title":"The dose threshold for nanoparticle tumour delivery","volume":"19","author":"Ouyang","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0285","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jnci\/90.13.978","article-title":"Double-Strand break repair deficiency and radiation sensitivity in BRCA2 mutant Cancer cells","volume":"90","author":"Abbott","year":"1998","journal-title":"JNCI: J. Nat. Cancer Institute"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021639","article-title":"Comprehensive genomic analysis of a BRCA2 deficient human pancreatic Cancer","volume":"6","author":"Barber","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0295","doi-asserted-by":"crossref","first-page":"14432","DOI":"10.1038\/ncomms14432","article-title":"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours","volume":"8","author":"Xu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0300","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0305","series-title":"Pharmacy, A Simple Practice Guide for Dose Conversion between Animals and Human","first-page":"27","volume":"vol. 7","author":"Nair","year":"2016"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0310","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2016.12.043","article-title":"In Vitro Dissolution Models for the Prediction of in Vivo Performance of an Oral Mesoporous Silica Formulation","volume":"250","author":"McCarthy","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0315","series-title":"Health Effects of Excess Copper, in: Copper in Drinking Water","author":"N.R. Council","year":"2000"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0320","series-title":"Critical Review of Exposure and Effects: Implications for Setting Regulatory Health Criteria for Ingested Copper","first-page":"131","volume":"65","author":"Taylor","year":"2020"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtemb.2014.06.004","article-title":"A study of dose response and organ susceptibility of copper toxicity in a rat model","volume":"29","author":"Kumar","year":"2015","journal-title":"J. Trace Elem. Med. Biol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0330","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/faat.1993.1122","article-title":"Subchronic toxicity of cupric sulfate administered in drinking water and feed to rats and mice","volume":"21","author":"H\u00e9bert","year":"1993","journal-title":"Fundament. Appl. Toxicol."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0335","article-title":"Novel combination therapies with the RNA polymerase I inhibitor CX-5461 significantly improve efficacy in multiple myeloma","volume":"130","author":"Maclachlan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0340","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.18632\/oncotarget.4093","article-title":"rRNA synthesis inhibitor, CX-5461, activates ATM\/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis","volume":"6","author":"Negi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0345","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.2147\/OTT.S104513","article-title":"CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma","volume":"9","author":"Li","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.jconrel.2022.03.004_bb0350","series-title":"CPX-351: Changing the Landscape of Treatment for Patients with Secondary Acute Myeloid Leukemia","first-page":"1147","volume":"vol. 14","author":"Talati","year":"2018"},{"key":"10.1016\/j.jconrel.2022.03.004_bb0355","series-title":"In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy","first-page":"129","volume":"33","author":"Tardi","year":"2009"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:17:02Z","timestamp":1759162622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":71,"alternative-id":["S0168365922001146"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DMPC\/Chol liposomal copper CX5461 is therapeutically superior to a DSPC\/Chol formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}